Buyers beware: Canberrans warned of dangerous and unknown substances in sport supplements

Canberrans using sports supplements for body building and weight loss are being warned of the health risks associated with these products that may contain dangerous substances.

ACT Chief Health Officer Dr Paul Kelly, said ACT Health is currently investigating the sale of sports and other supplements in the ACT, following complaints to the Health Protection Service.

“The sport supplements we are investigating contain a variety of substances, some of which can have significant impact on someone’s health when taken without advice from a health professional,” Dr Kelly said.

“The products are being sold locally and primarily through sports supplement stores, which is why this is so concerning and why Canberrans need to be warned.

“There is a myth – particularly in fitness communities – that if used in small amounts users will be safe, but even small amounts of these substances can put your health at risk.

“Our message to Canberrans is simple – buyers beware.

“These substances are banned for a reason. They pose a significant health risk and for the majority of these substances there is no legitimate medical use.

“We strongly advise users to stop taking these supplements immediately. Anyone concerned about their health should also contact their general practitioner for further advice,” Dr Kelly said.

The sport supplement products that have been found as part of the investigation, are labelled to contain substances, such as selective androgen receptor modulators (SARMs), cardarine, tadalafil, oxedrine, melatonin and phenibut.

It is not only illegal for supplement stores to supply these substances, but it is also illegal for people to possess some of these substances without a prescription.

Further information on substances in sports supplements is available on the ACT Health website at:

ACT Health’s investigation is ongoing, with further testing on a number of products currently underway. If anyone has information to support this investigation, please contact the Pharmaceutical Services Section of the Health Protection Service on 02 5124 9700 or

Statement ends

Page last updated on: 2 Jul 2019